![Boosters and time since the last anti-COVID-19 vaccine dose: lead public health choices by real-time epidemiological assessment | Epidemiologia&Prevenzione Boosters and time since the last anti-COVID-19 vaccine dose: lead public health choices by real-time epidemiological assessment | Epidemiologia&Prevenzione](https://epiprev.it/documenti/get_image.php?img=files/2022/ep1-2_2022/advance/art-russobooster.jpg)
Boosters and time since the last anti-COVID-19 vaccine dose: lead public health choices by real-time epidemiological assessment | Epidemiologia&Prevenzione
![Relative effectiveness of monovalent and bivalent mRNA boosters in preventing severe COVID-19 due to omicron BA.5 infection up to 4 months post-administration in people aged 60 years or older in Italy: a Relative effectiveness of monovalent and bivalent mRNA boosters in preventing severe COVID-19 due to omicron BA.5 infection up to 4 months post-administration in people aged 60 years or older in Italy: a](https://www.thelancet.com/cms/asset/a5db3686-c528-4236-93cf-6855cbd7db92/gr1.jpg)
Relative effectiveness of monovalent and bivalent mRNA boosters in preventing severe COVID-19 due to omicron BA.5 infection up to 4 months post-administration in people aged 60 years or older in Italy: a
![I can't update my Covid vaccine record to get a vital pass in Italy | Consumer affairs | The Guardian I can't update my Covid vaccine record to get a vital pass in Italy | Consumer affairs | The Guardian](https://i.guim.co.uk/img/media/d4650bdca7023a1305ebe1ddb73d74d57770f5ed/0_182_5472_3283/master/5472.jpg?width=1200&height=1200&quality=85&auto=format&fit=crop&s=3c8ad11a3c3ac7ebef29fea91b2e6c18)